Holen Sie sich die Stockscreener-App
78.97
0.93%
0.73
Überblick
Nachrichten
Preisverlauf
Optionskette
Financials
Warum fällt CVS?
Forum
Prognose
Aktiensplit
Dividendenhistorie
Schlusskurs vom Vortag:
$78.24
Offen:
$78.99
24-Stunden-Volumen:
13.70M
Relative Volume:
1.82
Marktkapitalisierung:
$100.25B
Einnahmen:
$393.94B
Nettoeinkommen (Verlust:
$428.00M
KGV:
206.40
EPS:
0.3826
Netto-Cashflow:
$6.29B
1W Leistung:
+5.29%
1M Leistung:
+1.84%
6M Leistung:
+22.89%
1J Leistung:
+43.19%
1-Tages-Spanne:
$78.15
$79.69
1-Wochen-Bereich:
$74.14
$80.50
52-Wochen-Spanne:
$43.56
$85.15
Cvs Health Corp Stock (CVS) Company Profile
Firmenname
Cvs Health Corp
Sektor
Branche
Telefon
(401) 765-1500
Adresse
ONE CVS DR., WOONSOCKET
Vergleichen Sie CVS mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
CVS
Cvs Health Corp
|
78.97 | 99.32B | 393.94B | 428.00M | 6.29B | 0.3826 |
|
UNH
Unitedhealth Group Inc
|
328.37 | 293.13B | 435.16B | 18.37B | 17.37B | 19.16 |
|
ELV
Elevance Health Inc
|
341.04 | 73.30B | 194.82B | 5.53B | 3.77B | 24.45 |
|
CI
Cigna Group
|
262.60 | 70.18B | 268.22B | 6.55B | 7.44B | 22.67 |
|
HUM
Humana Inc
|
256.66 | 30.12B | 123.11B | 1.58B | 2.44B | 13.03 |
Cvs Health Corp Stock (CVS) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-10-14 | Eingeleitet | Goldman | Buy |
| 2025-08-18 | Hochstufung | UBS | Neutral → Buy |
| 2025-08-14 | Hochstufung | Robert W. Baird | Neutral → Outperform |
| 2025-02-13 | Hochstufung | Leerink Partners | Market Perform → Outperform |
| 2025-02-12 | Hochstufung | Cantor Fitzgerald | Neutral → Overweight |
| 2025-01-30 | Hochstufung | Edward Jones | Hold → Buy |
| 2024-12-03 | Hochstufung | Deutsche Bank | Hold → Buy |
| 2024-11-18 | Hochstufung | Wells Fargo | Equal Weight → Overweight |
| 2024-10-10 | Hochstufung | Barclays | Equal Weight → Overweight |
| 2024-10-04 | Hochstufung | TD Cowen | Hold → Buy |
| 2024-05-30 | Eingeleitet | Robert W. Baird | Neutral |
| 2024-05-07 | Herabstufung | TD Cowen | Buy → Hold |
| 2024-05-02 | Herabstufung | UBS | Buy → Neutral |
| 2024-05-01 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
| 2024-05-01 | Herabstufung | Leerink Partners | Outperform → Market Perform |
| 2024-03-06 | Eingeleitet | Barclays | Equal Weight |
| 2024-02-26 | Eingeleitet | Leerink Partners | Outperform |
| 2023-12-22 | Eingeleitet | HSBC Securities | Buy |
| 2023-09-19 | Hochstufung | Evercore ISI | In-line → Outperform |
| 2023-09-12 | Hochstufung | Wolfe Research | Peer Perform → Outperform |
| 2023-08-18 | Herabstufung | Edward Jones | Buy → Hold |
| 2023-05-26 | Eingeleitet | Piper Sandler | Overweight |
| 2023-04-21 | Eingeleitet | Cantor Fitzgerald | Overweight |
| 2023-01-03 | Herabstufung | Evercore ISI | Outperform → In-line |
| 2022-11-23 | Fortgesetzt | Morgan Stanley | Overweight |
| 2022-06-17 | Eingeleitet | Loop Capital | Buy |
| 2022-05-27 | Herabstufung | Bernstein | Outperform → Mkt Perform |
| 2022-03-29 | Herabstufung | Deutsche Bank | Buy → Hold |
| 2022-02-11 | Herabstufung | Raymond James | Strong Buy → Outperform |
| 2021-12-14 | Eingeleitet | Goldman | Buy |
| 2021-12-01 | Eingeleitet | Seaport Research Partners | Buy |
| 2021-05-19 | Eingeleitet | Wells Fargo | Equal Weight |
| 2021-03-17 | Herabstufung | Guggenheim | Buy → Neutral |
| 2021-01-08 | Hochstufung | Jefferies | Hold → Buy |
| 2020-09-17 | Eingeleitet | Piper Sandler | Overweight |
| 2020-07-01 | Eingeleitet | SVB Leerink | Mkt Perform |
| 2020-05-14 | Hochstufung | Credit Suisse | Neutral → Outperform |
| 2019-09-27 | Fortgesetzt | RBC Capital Mkts | Outperform |
| 2019-09-12 | Eingeleitet | Deutsche Bank | Buy |
| 2019-06-05 | Hochstufung | Standpoint Research | Hold → Buy |
| 2019-04-29 | Herabstufung | Credit Suisse | Outperform → Neutral |
| 2019-04-18 | Eingeleitet | Guggenheim | Buy |
| 2019-04-15 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2019-04-10 | Bestätigt | BofA/Merrill | Buy |
| 2019-03-13 | Eingeleitet | Bernstein | Outperform |
| 2019-02-20 | Herabstufung | Wells Fargo | Outperform → Market Perform |
| 2019-01-17 | Eingeleitet | UBS | Buy |
| 2018-12-18 | Eingeleitet | Barclays | Overweight |
| 2018-11-29 | Fortgesetzt | Goldman | Neutral |
| 2018-11-28 | Eingeleitet | Evercore ISI | Outperform |
| 2018-10-26 | Fortgesetzt | Wolfe Research | Peer Perform |
| 2018-07-09 | Hochstufung | Citigroup | Neutral → Buy |
| 2018-02-27 | Fortgesetzt | BofA/Merrill | Buy |
| 2018-02-13 | Bestätigt | Citigroup | Neutral |
Alle ansehen
Cvs Health Corp Aktie (CVS) Neueste Nachrichten
CVS Health (CVS) Receives Analyst Price Target Upgrade to $98 | - GuruFocus
CVS Health (CVS) Sees Analyst Rating Update from Piper Sandler | - GuruFocus
CVS Health Is Seeing Margin And App Momentum, Analyst Highlights - Benzinga
CVS Health Targets Steady Gains With A Revamped Game Plan - Finimize
CVS Health Stock (CVS) Opinions on 2025 Guidance Update - Quiver Quantitative
CVS Health (CVS) Analysts Maintain Overweight, Raise Price Targe - GuruFocus
UBS Maintains Buy Rating, Raises Price Target for CVS to $97 | C - GuruFocus
CVS Health Raises Its Long-Term Outlook And Stock Follows Suit - Finimize
CVS forecasts 2026 profit higher than Wall Street estimates - Providence Business News
CVS Health Corporation (CVS) Sees Higher Price Target Despite PBM Pressures - Insider Monkey
Mizuho Raises Price Target for CVS Health (CVS) to $95.00 | CVS Stock News - GuruFocus
CVS Health (CVS) Receives Price Target Increase from Morgan Stan - GuruFocus
Cantor Fitzgerald reiterates Overweight rating on CVS Health stock - Investing.com
Piper Sandler raises CVS Health stock price target to $101 on growth outlook - Investing.com
CVS (CVS) Analyst Rating Update: Baird Raises Price Target to $9 - GuruFocus
Morgan Stanley raises CVS Health stock price target to $93 on turnaround - Investing.com
RBC Capital reiterates Outperform rating on CVS Health stock with $93 target - Investing.com
Truist Securities raises CVS Health stock price target to $98 on upbeat outlook - Investing.com
CVS Health stock price target raised to $97 from $96 at UBS - Investing.com
BofA Securities reiterates Buy rating on CVS Health stock with $100 target - Investing.com
CVS Health stock price target raised to $95 by Mizuho on positive outlook - Investing.com
TD Cowen raises CVS Health stock price target to $105 on Medicare Advantage recovery - Investing.com
How Recent Shifts Are Rewriting the Story for CVS Health - Yahoo Finance
3 Reasons CVS is Risky and 1 Stock to Buy Instead - Yahoo Finance
CVS raises profit forecast as turnaround plan takes effect - Honolulu Star-Advertiser
CVS forecasts 2026 profit above estimates as turnaround plan takes effect - Denver Gazette
CVS boosts profit outlook in sign of momentum as 2026 nears - The Boston Globe
CVS Health Hikes Its Outlook, and Says It Plans to Roll Out AI Platform - Investopedia
CVS Raises Profit Outlook in Sign of Momentum for 2026 - Transport Topics
Meet the 2.5% Yield Dividend Stock That Could Soar in 2026 - The Motley Fool
Is It Time to Bet on CVS Health? - StocksToTrade
CVS Health: Investor Day Targets Set Attractive Baseline For 2026 (CVS) - Seeking Alpha
CVS Forecasts 2026 Revenue Short of Wall Street Estimates - Bloomberg.com
Why CVS Health (CVS) Stock Is Up Today - Finviz
CVS Investor Day Highlights Major Growth AheadBullish Chart Into 2026 (NYSE:CVS) - Seeking Alpha
CVS Health raises guidance, predicts strong 2026 - Modern Healthcare
CVS Stock Rises Amid Positive Market Movement - GuruFocus
CVS Health lifts full-year guidance during investor event - Proactive financial news
Why Is CVS Health Stock Surging Today?CVS Health (NYSE:CVS) - Benzinga
CVS lifts outlook, Home Depot remains cautious, AutoZone earnings - Yahoo! Finance Canada
CVS Health Lifts Outlook And Sets Sights On AI Innovation - Finimize
CVS forecasts 2026 profit above estimates as turnaround plan takes effect By Reuters - Investing.com
CVS Health Corporation Provides Goodwill Impairment Guidance for the Year Ending December 31, 2025 - marketscreener.com
CVS Projects Mid-Teens EPS Growth through 2028 - GuruFocus
CVS Health (CVS) Boosts 2025 Financial Projections - GuruFocus
CVS Health Corporation Provides Earnings Guidance for the Full-Year 2026 - marketscreener.com
Nvidia, Warner Bros Discovery and CVS Health rise premarket; Toll Brothers falls - Investing.com
CVS forecasts 2026 profit above estimates on strong performance - BNN Bloomberg
CVS Health updates 2025 guidance, outlines mid-teens EPS growth target - Investing.com India
CVS Health Boosts FY25 Guidance, Expects Profit Growth in FY26 - marketscreener.com
CVS Health Corporation (CVS) Updates Strategic Priorities and Fi - GuruFocus
Finanzdaten der Cvs Health Corp-Aktie (CVS)
Umsatz
Nettogewinn
Free Cashflow
ENV
3.40%
0.04%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):